When is an asset-based (net asset / liquidation) valuation the most relevant approach, and what's its limitation?
A core Valuation interview question — asked in analyst and associate interviews across IB, PE, and the Big 4.
THE SHORT ANSWER
An asset-based approach values the company as the fair value of its assets less liabilities, rather than as a going concern earning cash flows. It's most relevant for asset-heavy holding entities, real-estate or investment companies, financial institutions valued on book/tangible book, and distressed or loss-making businesses where the liquidation/break-up value sets a floor below which the equity shouldn't trade. It's also a useful sanity floor in any valuation. Its limitation is that for a profitable operating business it ignores the going-concern premium — the value of assembled assets generating cash flows, intangibles, brand, and growth — so it systematically understates a healthy company. It also depends heavily on whether you use replacement cost, fair market value, or forced-liquidation values, which can differ widely. So it's a floor and a special-case method, not the primary tool for a going concern with earning power.
WHAT INTERVIEWERS LISTEN FOR
- ✓Values fair value of assets minus liabilities, not cash flows
- ✓Best for asset-heavy/holding/financial/distressed firms
- ✓Sets a floor (liquidation value) for the equity
- ✓Ignores going-concern premium/intangibles for healthy operating firms
COMMON MISTAKES
- ✗Using it as primary for a profitable operating company
- ✗Ignoring the going-concern value
- ✗Confusing replacement vs liquidation values
Reading isn't the same as answering under pressure.
Interviewers don't hand you the model answer — you deliver yours on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- How do you value a company with no revenue?
- Explain accretion/dilution analysis.
- How would you value a company in a cyclical industry?
- What is the most appropriate valuation methodology for a company with significant intangible assets but no current revenue, such as a biotech startup in the pre-clinical stage?
- When calculating WACC for a company with multiple divisions in different countries, what is the correct approach?
- How does a private equity buyer use an LBO to set the maximum price it can pay, and why is this a valuation floor?